Curi RMB Capital LLC Sells 358 Shares of Bristol-Myers Squibb (NYSE:BMY)

Curi RMB Capital LLC reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,535 shares of the biopharmaceutical company’s stock after selling 358 shares during the period. Curi RMB Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,161,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Bristol-Myers Squibb by 21.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 13,698,400 shares of the biopharmaceutical company’s stock valued at $774,734,000 after buying an additional 2,417,456 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Bristol-Myers Squibb by 18.2% during the 4th quarter. First Trust Advisors LP now owns 1,312,733 shares of the biopharmaceutical company’s stock valued at $74,248,000 after acquiring an additional 202,232 shares during the period. Forum Financial Management LP raised its stake in Bristol-Myers Squibb by 47.8% during the 4th quarter. Forum Financial Management LP now owns 16,884 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 5,462 shares during the period. Freedom Investment Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 51.3% in the 4th quarter. Freedom Investment Management Inc. now owns 17,806 shares of the biopharmaceutical company’s stock worth $1,007,000 after purchasing an additional 6,040 shares in the last quarter. Finally, Capital International Ltd. CA lifted its stake in shares of Bristol-Myers Squibb by 0.8% in the fourth quarter. Capital International Ltd. CA now owns 60,180 shares of the biopharmaceutical company’s stock valued at $3,404,000 after buying an additional 452 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. UBS Group decreased their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Cantor Fitzgerald upped their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Finally, Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $57.67.

Bristol-Myers Squibb Stock Down 0.3 %

Shares of NYSE BMY opened at $49.24 on Monday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company has a market cap of $100.18 billion, a P/E ratio of -11.14, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The business has a 50-day simple moving average of $56.98 and a two-hundred day simple moving average of $56.68.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.04%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.07% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.